Saudi Arabia becomes first country to approve AI app that reads vital signs from your face

Your smartphone camera can already scan documents, identify plants, and translate text in real time. Now, Saudi Arabia has approved an AI-powered app that uses it to monitor your vital signs.

The Saudi Food and Drug Authority (SFDA) has granted marketing authorization for a digital medical application that measures heart rate, blood oxygen saturation, and blood pressure using a smartphone camera. According to the SFDA, this makes Saudi Arabia the first country in the world to approve this specific application for the market.

The approval followed a full technical and clinical review, including a dedicated clinical trial conducted inside Saudi Arabia. The app was developed through a collaboration between the SFDA and the Ministry of Health, with the Seha Virtual Hospital playing a central role in testing and evaluation.

How does it work?

The app uses a technology called remote photoplethysmography, or rPPG. The basic idea is that blood moving through your face causes tiny, nearly invisible changes in skin color with each heartbeat. The camera picks up those changes, and the AI algorithms translate them into readings for heart rate and oxygen levels.

Blood pressure measurement works slightly differently and requires a one-time calibration step using a certified medical device before the app can produce readings on its own.

A few important limits to know:

• It is not a standalone diagnostic tool
• It is not designed for emergency or critical care situations
• The initial blood pressure calibration must be done with an approved medical device

The app went through the SFDA's Regulatory Sandbox before moving to its Innovative Medical Devices pathway, where it completed all required evaluations including the Saudi-based clinical trial.

Why does it matter?

Getting your blood pressure or heart rate checked typically means visiting a clinic, using a dedicated device, or owning wearable hardware. An approved smartphone-based alternative could change that for a lot of people, particularly in remote areas or for patients managing chronic conditions at home.

The broader significance is regulatory. Health tech companies building similar tools now have a concrete approval precedent to reference. Saudi Arabia beating larger markets like the US and EU to a first approval of this kind is also notable, since it signals that the SFDA is willing to move quickly on digital health products when the clinical evidence supports it.

For consumers, the practical value depends on accuracy in real-world conditions, which the clinical trial was designed to assess. The calibration requirement for blood pressure suggests the developers and regulators are being careful about where the technology's limits currently sit.

The context

This approval fits into a larger push by Saudi Arabia to modernize its healthcare system under Vision 2030, the country's long-term economic and social reform plan. The Health Sector Transformation Program, one of Vision 2030's components, has set digital health as a priority area.

The SFDA has been building out its regulatory infrastructure for AI and digital medical devices over the past few years. The Regulatory Sandbox, which this app passed through, is designed to give innovative products a structured path to approval without forcing them into frameworks built for traditional hardware devices.

Remote photoplethysmography is not a new concept in research, but getting it into a regulated, commercially approved product has proven difficult in most markets. Companies like Apple and Samsung have explored camera-based health monitoring in their devices, though these are generally positioned as wellness features rather than medical ones. A full regulatory clearance for a medical-grade app in this category is a meaningful step forward for the field.

The approval was announced during what Saudi Arabia has designated the Year of Artificial Intelligence 2026, a national initiative aimed at accelerating AI adoption across key sectors.